NASDAQ:TELO Telomir Pharmaceuticals (TELO) Stock Price, News & Analysis $1.20 -0.03 (-2.44%) Closing price 04:00 PM EasternExtended Trading$1.19 -0.01 (-0.83%) As of 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsNews and TrendsOwnershipSEC Filings About Telomir Pharmaceuticals Stock (NASDAQ:TELO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get TELO alerts:Sign Up Key Stats Today's Range$1.17▼$1.2450-Day Range$1.05▼$1.2552-Week Range$0.89▼$2.09Volume72,108 shsAverage Volume69,518 shsMarket Capitalization$82.54 millionP/E RatioN/ADividend YieldN/APrice Target$4.00Consensus RatingHold Company Overview Telomir Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing therapies for diseases and conditions associated with aging. The company’s research is centered on telomere biology, an area involving the protective structures at the ends of chromosomes that generally shorten as cells divide and age. Telomir’s lead product candidate is TELOMIR-1, an orally administered small-molecule compound being investigated for its potential to address telomere shortening and support healthier cellular aging. The company has described potential applications in age-related diseases affecting humans and companion animals, although TELOMIR-1 remains in development and has not been approved as a treatment. Telomir Pharmaceuticals is headquartered in the United States and is advancing its programs through preclinical research and development activities. Publicly available information about its broader pipeline, commercial operations, geographic reach and leadership team is limited.AI Generated. May Contain Errors. Read More Telomir Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks40th Percentile Overall ScoreTELO MarketRank™: Telomir Pharmaceuticals scored higher than 40% of companies evaluated by MarketBeat, and ranked 681st out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingHold Consensus RatingTelomir Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialTelomir Pharmaceuticals has a consensus price target of $4.00, representing about 233.3% upside from its current price of $1.20.Amount of Analyst CoverageTelomir Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Telomir Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Telomir Pharmaceuticals is -1.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Telomir Pharmaceuticals is -1.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTelomir Pharmaceuticals has a P/B Ratio of 7.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Telomir Pharmaceuticals' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.35% of the float of Telomir Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverTelomir Pharmaceuticals has a short interest ratio ("days to cover") of 19.7, which indicates bearish sentiment.Change versus previous monthShort interest in Telomir Pharmaceuticals has recently decreased by 5.19%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTelomir Pharmaceuticals does not currently pay a dividend.Dividend GrowthTelomir Pharmaceuticals does not have a long track record of dividend growth. News and Social Media1.8 / 5News Sentiment-0.11 News SentimentTelomir Pharmaceuticals has a news sentiment score of -0.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Telomir Pharmaceuticals this week, compared to 1 article on an average week.MarketBeat Follows3 people have added Telomir Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership0.6 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Telomir Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders16.36% of the stock of Telomir Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsTelomir Pharmaceuticals has minimal institutional ownership at this time.Read more about Telomir Pharmaceuticals' insider trading history. Receive TELO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Telomir Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TELO Stock News HeadlinesResearch shows Telomir-Zn might slow bone cancer in dogsSeptember 24, 2026 | msn.comMaxim Initiates Telomir Pharmaceuticals at Buy With $4 Price TargetSeptember 18, 2026 | marketscreener.comMTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.September 28 at 1:00 AM | Porter & Company (Ad)Telomir Publishes Data Validating Telomir-Zn For AMD Alongside Cancer Indications; Stock UpSeptember 17, 2026 | rttnews.comTelomir-Zn Preclinical Data Highlight Retinal Regeneration PotentialSeptember 17, 2026 | tipranks.comTelomir Announces Peer-Reviewed Publication Showing Telomir-Zn Restores Visual Function and Retinal Structure in a Model of Age-Related Macular Degeneration (AMD)September 17, 2026 | globenewswire.comTelomir unveils new preclinical data for Telomir-ZnSeptember 14, 2026 | tipranks.comTelomir Announces Research with The Ohio State University Demonstrating In-Vitro Anti-Cancer Activity in Human and Canine Osteosarcoma ModelsSeptember 14, 2026 | globenewswire.comSee More Headlines TELO Stock Analysis - Frequently Asked Questions How have TELO shares performed this year? Telomir Pharmaceuticals' stock was trading at $1.33 at the beginning of the year. Since then, TELO stock has decreased by 9.8% and is now trading at $1.20. How were Telomir Pharmaceuticals' earnings last quarter? Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) announced its earnings results on Thursday, August, 13th. The company reported ($0.79) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by $0.72. When did Telomir Pharmaceuticals IPO? Telomir Pharmaceuticals (TELO) raised $7 million in an initial public offering on Friday, February 9th 2024. The company issued 1,000,000 shares at $7.00 per share. Kingswood Investments served as the underwriter for the IPO. Who are Telomir Pharmaceuticals' major shareholders? Telomir Pharmaceuticals' top institutional investors include BlackRock Inc. (0.41%), Bank of New York Mellon Corp (0.07%) and OneDigital Investment Advisors LLC (0.03%). How do I buy shares of Telomir Pharmaceuticals? Shares of TELO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/13/2026Today9/28/2026Next Earnings (Estimated)12/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3d) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 As of 3 days ago, TELO's financial health entered the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:TELO Previous SymbolNASDAQ:TELO CIK1971532 Webtelomirpharma.com Phone(786) 396-6723FaxN/AEmployees5Year FoundedN/APrice Target and Rating Average Price Target for Telomir Pharmaceuticals$4.00 High Price Target$4.00 Low Price Target$4.00 Potential Upside/Downside+233.3%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($0.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$10.41 million Net MarginsN/A Pretax MarginN/A Return on Equity-102.70% Return on Assets-90.75% Debt Debt-to-Equity RatioN/A Current Ratio16.16 Quick Ratio16.16 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.17 per share Price / Book7.06Miscellaneous Outstanding Shares68,780,000Free Float57,523,000Market Cap$82.54 million OptionableN/A Beta-0.25 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:TELO) was last updated on 9/28/2026 by MarketBeat.com Staff. From Our PartnersA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredAnalyst nicknamed “The Prophet” issues new warning for AmericaWhitney Tilson exposed a major company on 60 Minutes in an Emmy-winning investigation - the stock lost nearly ...Stansberry Research | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredElon Musk’s Hushed FCC Filing. Dec 8th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredDid you forget to grab this?Most beginners stay stuck on the sidelines for years because no one shows them the simple steps between being ...Profits Run | SponsoredThis AI Stock Reminds One Analyst of Early NvidiaJeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Telomir Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Telomir Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
